On Oct 09, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $6 to $25.
BofA Securities analyst Tazeen Ahmad maintains with a sell rating, and adjusts the target price from $14 to $6.
TD Cowen analyst Ritu Baral downgrades to a hold rating, and adjusts the target price from $16 to $10.
Baird analyst Joel Beatty maintains with a hold rating, and adjusts the target price from $13 to $9.
Needham analyst Ami Fadia maintains with a hold rating.
Stifel analyst Paul Matteis maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Following the Phase 2 LIGHTWAVE study results, where dalzanemdor did not meet the primary endpoint in Alzheimer's disease, and the subsequent announcement that development in this indication would not continue, the outlook on Sage Therapeutics has been impacted. Despite this setback, the company anticipates topline Phase 2 results from the DIMENSION trial assessing dalzanemdor in Huntington's disease later in the year. Initial positive findings from the SURVEYOR trials have provided some clinical substantiation; however, it's noted that substantial clinical proof is still required to mitigate risks associated with the program.
Sage Therapeutics' Phase 2 LIGHTWAVE study of dalzanemdor in mild Alzheimer's Disease/Mild Cognitive Impairment did not achieve a statistically significant improvement from the base measurement on the primary goal of WAIS-IV score change. It has been noted that this outcome was not factored into prior forecasts, therefore no adjustments are necessary. Sage is halting further development of dalzanemdor in Alzheimer's Disease, yet anticipates results from the DIMENSION study in Huntington's disease by the fourth quarter of 2024. Due to previous setbacks with dalzanemdor, there is a cautious stance regarding the likelihood of significant results in the upcoming Huntington's disease data readout.
Sage Therapeutics' recent announcement of the phase 2 LIGHTWAVE trial's failure of dalzanemdor in treating Alzheimer's disease has shifted the entirety of investor attention towards the prospects of Zurzuvae.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
